BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2466 related articles for article (PubMed ID: 9403702)

  • 21. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.
    Okada F; Rak JW; Croix BS; Lieubeau B; Kaya M; Roncari L; Shirasawa S; Sasazuki T; Kerbel RS
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3609-14. PubMed ID: 9520413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
    Borgström P; Gold DP; Hillan KJ; Ferrara N
    Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma.
    Brown LF; Tognazzi K; Dvorak HF; Harrist TJ
    Am J Pathol; 1996 Apr; 148(4):1065-74. PubMed ID: 8644848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis.
    Breier G; Blum S; Peli J; Groot M; Wild C; Risau W; Reichmann E
    Int J Cancer; 2002 Jan; 97(2):142-8. PubMed ID: 11774256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
    Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
    Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.
    Claffey KP; Brown LF; del Aguila LF; Tognazzi K; Yeo KT; Manseau EJ; Dvorak HF
    Cancer Res; 1996 Jan; 56(1):172-81. PubMed ID: 8548760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium.
    Mukhopadhyay D; Nagy JA; Manseau EJ; Dvorak HF
    Cancer Res; 1998 Mar; 58(6):1278-84. PubMed ID: 9515816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts.
    Kurebayashi J; Otsuki T; Kurosumi M; Soga S; Akinaga S; Sonoo H
    Jpn J Cancer Res; 2001 Dec; 92(12):1342-51. PubMed ID: 11749701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.
    Niu G; Wright KL; Huang M; Song L; Haura E; Turkson J; Zhang S; Wang T; Sinibaldi D; Coppola D; Heller R; Ellis LM; Karras J; Bromberg J; Pardoll D; Jove R; Yu H
    Oncogene; 2002 Mar; 21(13):2000-8. PubMed ID: 11960372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
    Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
    Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.
    Brown LF; Detmar M; Claffey K; Nagy JA; Feng D; Dvorak AM; Dvorak HF
    EXS; 1997; 79():233-69. PubMed ID: 9002222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.
    Kondo S; Asano M; Suzuki H
    Biochem Biophys Res Commun; 1993 Aug; 194(3):1234-41. PubMed ID: 7688963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway.
    Clarke K; Smith K; Gullick WJ; Harris AL
    Br J Cancer; 2001 May; 84(10):1322-9. PubMed ID: 11355942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
    Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
    Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.
    Lee JS; Kim HS; Jung JJ; Kim YB; Lee MC; Park CS
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):289-95. PubMed ID: 12607595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
    Kerbel RS; Viloria-Petit A; Klement G; Rak J
    Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription.
    Reisinger K; Kaufmann R; Gille J
    J Cell Sci; 2003 Jan; 116(Pt 2):225-38. PubMed ID: 12482909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 124.